Adele Stewart

Dr. Adele Stewart

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2010 in Circulation Research
Verified
Journal Article
Closed access
PDF file
JYJianqi Yang
Jianqi Yang
JHJie Huang
Jie Huang
BMBiswanath Maity
Biswanath Maity
ZGZhan Gao
Zhan Gao
RLRamón A. Lorca
Ramón A. Lorca
RFRory A. Fisher
Rory A. Fisher
Rationale:: Parasympathetic regulation of heart rate is mediated by acetylcholine binding to G protein–coupled muscarinic M2 receptors, which activate heterotrimeric G i/o proteins to promote G protein–coupled inwardly rectifying K + (GIRK) channel activation. Regulator of G protein signaling (RGS) proteins, which function to inactivate G proteins, are indispensable for normal parasympathetic control of the heart. However, it is unclear which of the more than 20 known RGS proteins function to negatively regulate and thereby ensure normal parasympathetic control of the heart. Objective:: To examine the specific contribution of RGS6 as an essential regulator of parasympathetic signaling in heart. Methods and Results:: We developed RGS6 knockout mice to determine the functional impact of loss of RGS6 on parasympathetic regulation of cardiac automaticity. RGS6 exhibited a uniquely robust expression in the heart, particularly in sinoatrial and atrioventricular nodal regions. Loss of RGS6 provoked dramatically exaggerated bradycardia in response to carbachol in mice and isolated perfused hearts and significantly enhanced the effect of carbachol on inhibition of spontaneous action potential firing in sinoatrial node cells. Consistent with a role of RGS6 in G protein inactivation, RGS6-deficient atrial myocytes exhibited a significant reduction in the time course of acetylcholine-activated potassium current ( I K ACh ) activation and deactivation, as well as the extent of I K ACh desensitization. Conclusions:: RGS6 is a previously unrecognized, but essential, regulator of parasympathetic activation in heart, functioning to prevent parasympathetic override and severe bradycardia. These effects likely result from actions of RGS6 as a negative regulator of G protein activation of GIRK channels.

1 January 2015
Verified
Book Chapter
Closed access
ASAdele Stewart
Adele Stewart
RFRory A. Fisher
Rory A. Fisher

14 March 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JYJianqi Yang
Jianqi Yang
BMBiswanath Maity
Biswanath Maity
JHJie Huang
Jie Huang
ZGZhan Gao
Zhan Gao
ASAdele Stewart
Adele Stewart
RFRory A. Fisher
Rory A. Fisher
Clinical use of the widely used chemotherapeutic agent doxorubicin is limited by life-threatening cardiotoxicity. The mechanisms underlying doxorubicin-induced cardiomyopathy and heart failure remain unclear but are thought to involve p53-mediated myocardial cell apoptosis. The tripartite G-protein inactivating protein RGS6 has been implicated in reactive oxygen species (ROS) generation, ATM/p53 activation, and apoptosis in doxorubicin-treated cells. Thus, we hypothesized that RGS6, the expression of which is enriched in cardiac tissue, might also be responsible for the pathologic effects of doxorubicin treatment in heart. In this study, we show that RGS6 expression is induced strongly by doxorubicin in the ventricles of mice and isolated ventricular myocytes via a posttranscriptional mechanism. While doxorubicin-treated wild-type (WT) mice manifested severe left ventricular dysfunction, loss of heart and body mass, along with decreased survival 5 days after doxorubicin administration, mice lacking RGS6 were completely protected against these pathogenic responses. Activation of ATM/p53 apoptosis signaling by doxorubicin in ventricles of WT mice was also absent in their RGS6−/− counterparts. Doxorubicin-induced ROS generation was dramatically impaired in both the ventricles and ventricular myocytes isolated from RGS6−/− mice, and the apoptotic response to doxorubicin in ventricular myocytes required RGS6-dependent ROS production. These results identify RGS6 as an essential mediator of the pathogenic responses to doxorubicin in heart, and they argue that RGS6 inhibition offers a rational means to circumvent doxorubicin cardiotoxicity in human patients with cancer. Cancer Res; 73(6); 1662–7. ©2012 AACR.

1 February 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BMBiswanath Maity
Biswanath Maity
ASAdele Stewart
Adele Stewart
JYJianqi Yang
Jianqi Yang
LLLipin Loo
Lipin Loo
DSDavid Sheff
David Sheff
RFRory A. Fisher
Rory A. Fisher
γ-Aminobutyric acid (GABA) release from inhibitory interneurons located within the cerebellar cortex limits the extent of neuronal excitation in part through activation of metabotropic GABAB receptors. Stimulation of these receptors triggers a number of downstream signaling events, including activation of GIRK channels by the Gβγ dimer resulting in membrane hyperpolarization and inhibition of neurotransmitter release from presynaptic sites. Here, we identify RGS6, a member of the R7 subfamily of RGS proteins, as a key regulator of GABABR signaling in cerebellum. RGS6 is enriched in the granule cell layer of the cerebellum along with neuronal GIRK channel subunits 1 and 2 where RGS6 forms a complex with known binding partners Gβ5 and R7BP. Mice lacking RGS6 exhibit abnormal gait and ataxia characterized by impaired rotarod performance improved by treatment with a GABABR antagonist. RGS6−/− mice administered baclofen also showed exaggerated motor coordination deficits compared with their wild-type counterparts. Isolated cerebellar neurons natively expressed RGS6, GABABR, and GIRK channel subunits, and cerebellar granule neurons from RGS6−/− mice showed a significant delay in the deactivation kinetics of baclofen-induced GIRK channel currents. These results establish RGS6 as a key component of GABABR signaling and represent the first demonstration of an essential role for modulatory actions of RGS proteins in adult cerebellum. Dysregulation of RGS6 expression in human patients could potentially contribute to loss of motor coordination and, thus, pharmacological manipulation of RGS6 levels might represent a viable means to treat patients with ataxias of cerebellar origin.

13 January 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ASAdele Stewart
Adele Stewart
BMBiswanath Maity
Biswanath Maity
AWAmanda M. Wunsch
Amanda M. Wunsch
FMFantao Meng
Fantao Meng
QWQi Wu
Qi Wu
RFRory A. Fisher
Rory A. Fisher
Targeting serotonin (5‐HT) bioavailability with selective 5‐HT reuptake inhibitors (SSRIs) remains the most widely used treatment for mood disorders. However, their limited efficacy, delayed onset of action, and side effects restrict their clinical utility. Endogenous regulator of G‐protein signaling (RGS) proteins have been implicated as key inhibitors of 5‐HT 1A Rs, whose activation is believed to underlie the beneficial effects of SSRIs, but the identity of the specific RGS proteins involved remains unknown. We identify RGS6 as the critical negative regulator of 5‐HT 1A R‐dependent antidepressant actions. RGS6 is enriched in hippocampal and cortical neurons, 5‐HT 1A R‐expressing cells implicated in mood disorders. RGS6 –/– mice exhibit spontaneous anxiolytic and antidepressant behavior rapidly and completely reversibly by 5‐HT 1A R blockade. Effects of the SSRI fluvoxamine and 5‐HT 1A R agonist 8‐OH‐DPAT were also potentiated in RGS6 –/– mice. The phenotype of RGS6 –/– mice was associated with decreased CREB phosphorylation in the hippocampus and cortex, implicating enhanced Gα 1 ‐dependent adenylyl cyclase inhibition as a possible causative factor in the behavior observed in RGS6 –/– animals. Our results demonstrate that by inhibiting serotonergic innervation of the cortical‐limbic neuronal circuit, RGS6 exerts powerful anxiogenic and prodepressant actions. These findings indicate that RGS6 inhibition may represent a viable means to treat mood disorders or enhance the efficacy of serotonergic agents.—Stewart, A., Maity, B., Wunsch, A. M., Meng, F., Wu, Q., Wemmie, J. A., Fisher, R. A. Regulator of G‐protein signaling 6 (RGS6) promotes anxiety and depression by attenuating serotonin‐mediated activation of the 5‐HT 1A receptor‐adenylyl cyclase axis. FASEB J. 28, 28–1735 (1744). www.fasebj.org

2 February 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ASAdele Stewart
Adele Stewart
BMBiswanath Maity
Biswanath Maity
SASimon P. Anderegg
Simon P. Anderegg
CAChantal Allamargot
Chantal Allamargot
JYJianqi Yang
Jianqi Yang
RFRory A. Fisher
Rory A. Fisher
Significance: Almost 20% of women and 40% of men in the United States abuse alcohol or have experienced alcohol dependence in their lifetime. Though accidents, traffic fatalities, and violent crimes account for the majority of alcohol-involved mortalities, excessive, chronic drinking also causes often irreversible heart and liver damage. We identify regulator of G protein signaling 6 (RGS6) as a novel drug target with substantive potential clinical utility in the treatment of alcoholism and amelioration of the resultant hepatic and cardiac toxicity. Mice lacking RGS6 exhibit a reduction in voluntary alcohol consumption, conditioned reward and withdrawal. In addition,RGS6−/−mice are largely protected from alcohol-induced cardiomyopathy, hepatic steatosis, gastrointestinal barrier dysfunction, and endotoxemia. Thus, targeting RGS6 could reduce alcohol cravings while simultaneously protecting the heart and liver from damage.